FDA Approves TREGZI, Adding a Donor Immune Cell-Reprogrammed Option for Blood Cancer Transplant Treatment

For many patients with blood cancers, allogeneic hematopoietic stem cell transplantation is often a key therapy on the path to long-term remission, but it also comes with a heavy cost: the donor-derived immune system may attack the patient’s body, causing graft-versus-host disease. The U.S. Food and Drug Administration’s approval of Orca Bio’s TREGZI represents a newly regulator-recognized solution to this long-standing dilemma.

TREGZI is also known clinically as Orca-T. It is indicated for adult patients with hematologic malignancies who undergo matched donor hematopoietic stem cell transplantation after myeloablative conditioning, to improve “chronic graft-versus-host disease-free survival.” The FDA has added it to its list of approved cell and gene therapy products, with the product category labeled as an allogeneic regulatory T-cell immunotherapy containing hematopoietic stem cells and T cells, and the manufacturer listed as Orca Biosystems Inc.

The core of this therapy is that it does not use a traditional unselected graft, but instead prepares a specific combination from matched donor cells for each patient. The prescribing information shows that TREGZI is supplied in four separate infusion bags, containing hematopoietic stem/progenitor cells, regulatory T cells, conventional T cells, and conventional T-cell diluent. The regulatory T cells are designed to help tame the immune response, while the conventional T cells preserve immune functions that may be important for infection and tumor surveillance.

The approval is based on a randomized, multicenter Phase 3 Precision-T study that enrolled 187 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia. Data released by Orca Bio show that at 12 months, chronic graft-versus-host disease-free survival was 78% in the TREGZI group and 38% in the conventional allogeneic hematopoietic stem cell transplantation group; overall survival was 94% and 83%, respectively.

These figures mean that the significance of TREGZI is not only that it is “one more transplant product,” but that it pushes the immune balance in transplant medicine, which has long relied on experience-based modulation, toward a more precise design of cellular composition. However, the publicly available summaries still cannot answer all clinical questions, such as how different disease subtypes, relapse-risk levels, and transplant center experience will affect real-world benefit and accessibility.

Safety likewise should not be obscured by efficacy signals. The warnings listed in the prescribing information include graft failure, graft-versus-host disease, infusion reactions, secondary malignancies or donor-derived malignancies, and transmission of infectious pathogens. In other words, TREGZI attempts to reduce the burden of chronic GVHD, but it does not eliminate the high-risk nature of allogeneic transplantation itself.

This approval also highlights that cell therapy is moving from a single anticancer attack tool toward more complex immune system engineering. For patients and physicians, the real questions will be more pragmatic: who is most likely to benefit, whether preparation and scheduling can align with transplant timing, whether long-term follow-up will maintain the early advantage, and whether this type of personalized donor cell product can be implemented reliably beyond a small number of specialized centers.